Literature DB >> 23601711

Preparation of S14161 and its analogues and the discovery of 6-bromo-8-ethoxy-3-nitro-2H-chromene as a more potent antitumor agent in vitro.

Shu-Qiang Yin1, Min Shi, Ting-Ting Kong, Cheng-Mei Zhang, Kunkun Han, Biyin Cao, Zubin Zhang, Xiaolin Du, Long-Qian Tang, Xinliang Mao, Zhao-Peng Liu.   

Abstract

The small chemical compound 8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene (S14161) was recently identified as an inhibitor of the phosphoinositide 3-kinase (PI3K). In the present study, we designed a novel synthesis of S14161 and prepared a series of its analogues via the oxa-Michael-Henry reaction in the presence of catalytic amounts of l-proline and triethylamine. Further structural simplification led to the identification of 6-bromo-8-ethoxy-3-nitro-2H-chromene (BENC-511) that exhibited potent antiproliferative activities against a panel of 12 tumor cell lines. Compared with S14161, BENC-511 was more potent in blocking the AKT phosphorylation and inducing cancer cell apoptosis. BENC-511 also displayed more potent effects on human umbilical vein epithelial cells (HUVEC) migration, suggesting its anti-angiogenesis activity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23601711     DOI: 10.1016/j.bmcl.2013.03.097

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Modulation of platelet activation and thrombus formation using a pan-PI3K inhibitor S14161.

Authors:  Wenxiu Yi; Qiang Li; Jian Shen; Lijie Ren; Xiaohui Liu; Qi Wang; Sudan He; Qingyu Wu; Hu Hu; Xinliang Mao; Li Zhu
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

2.  Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.

Authors:  Kunkun Han; Xin Xu; Guodong Chen; Yuanying Zeng; Jingyu Zhu; Xiaolin Du; Zubin Zhang; Biyin Cao; Zhaopeng Liu; Xinliang Mao
Journal:  J Hematol Oncol       Date:  2014-01-15       Impact factor: 17.388

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.